title: Effect of a cysteinyl leukotriene antagonist, pranlukast hydrate, on acetaldehyde-induced bronchoconstriction in asthmatic patients.
abstract: Acetaldehyde is a main factor of alcohol-induced asthma. We previously reported that the cysteinyl leukotriene (cys-LT) receptor antagonist, pranlukast hydrate, inhibits acetaldehyde-induced airway hyperresponsiveness in guinea pigs. The purpose of this study was to evaluate the involvement of cys-LT on bronchial responsiveness to acetaldehyde in asthmatic patients. We investigated the bronchial response to inhalation of acetaldehyde in 10 asthmatic patients, who were treated with placebo or pranlukast hydrate (225.5 mg), a cys-LT receptor antagonist, twice a day for 1 wk using a double-blind, randomized, placebo-controlled, cross-over design. Although a remarkable improvement of acetaldehyde bronchoconstriction was observed in 3 out of 10 subjects, PC(20)-AcCHO values were identical between placebo [12.0 (GSEM, 1.192) mg/ml] and pranlukast [14.7 (GSEM, 1.245) mg/ml] groups. The changes in bronchial responsiveness to acetaldehyde were similar in the six patients who had never experienced alcohol-induced asthma and the four who had. In conclusion, cys-LTs are not involved in acetaldehyde-induced bronchoconstriction.
authors.affiliation: The Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa, Japan. myous@nifty.com
authors.forename: S
authors.initials: S
authors.lastname: Myou
authors.forename: M
authors.initials: M
authors.lastname: Fujimura
authors.forename: Y
authors.initials: Y
authors.lastname: Kamio
authors.forename: T
authors.initials: T
authors.lastname: Kita
authors.forename: N
authors.initials: N
authors.lastname: Katayama
authors.forename: M
authors.initials: M
authors.lastname: Abo
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshimi
authors.forename: M
authors.initials: M
authors.lastname: Nishitsuji
authors.forename: S
authors.initials: S
authors.lastname: Nomura
authors.forename: T
authors.initials: T
authors.lastname: Hashimoto
authors.forename: S
authors.initials: S
authors.lastname: Nakao
mesh_terms: D000079:Acetaldehyde / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D001249:Asthma / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D016084:Bronchoconstriction / Q000187:drug effects*; D002867:Chromones / Q000008:administration & dosage / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003545:Cysteine / Q000037:antagonists & inhibitors*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D015289:Leukotrienes; D008297:Male; D008875:Middle Aged; D010919:Placebos
chemical_list: D002867:Chromones; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D010919:Placebos; C112381:cysteinyl-leukotriene; D000079:Acetaldehyde; D003545:Cysteine; C047681:pranlukast